Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Botulinum Toxin Type A for Injection to Treat Glabellar Lines

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Moderate or severe glabellar frown lines~* Female or male, 30 to 65 years of age in good general health~* Women of childbearing potential must agree to use an effective method of birth control during the course of the study~* Willing to refrain from receipt of facial fillers, laser treatments or use of products that affect skin remodeling and causes an active dermal response~Exclusion Criteria:~* Any neurological condition that may place the subject at increased risk with exposure to Botulinum Toxin Type A such as amyotrophic lateral sclerosis and motor neuropathy, Lambert-Eaton syndrome, and myasthenia gravis~* Muscle weakness or paralysis, particularly in the treatment area~* Active skin disease or infections or irritation at the treatment area~* Facial asymmetry, deep dermal scarring, or inability to substantially lessen the glabellar frown lines by manually spreading them apart~* Treatment with Botulinum Toxin Type A in the face in the last 6 months or in the last 3 months anywhere in the body

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Dose A (Type: EXPERIMENTAL): Dose A: Botulinum Toxin Type A
- Dose B (Type: EXPERIMENTAL): Dose B: Botulinum Toxin Type A
- Dose C (Type: EXPERIMENTAL): Dose C: Botulinum Toxin Type A
- Dose D (Type: ACTIVE_COMPARATOR): Dose D: Botulinum Toxin Type A
- Dose E (Type: PLACEBO_COMPARATOR): Dose E: Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).